Celavie Biosciences, Llc Take On Regenerative Stem Cell Therapy

  October 8th 2019    
Notice: Use of undefined constant ” - assumed '”' in /home/linkinstmcell/public_html/wp-content/themes/chicago/single.php on line 31

Notice: Use of undefined constant “ - assumed '“' in /home/linkinstmcell/public_html/wp-content/themes/chicago/single.php on line 31
Blog

Celavie Biosciences (LLC) is a company who is working to improve lives and restore hope by advancing innovations in central nervous system (CNS) diseases with regenerative stem cell-based therapies, announced on 1st October their attendance at the Alliance of Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Mesa was held on October 2nd – 4th in Carlsbad, California.
Sandy Solmon, CEO and President, and Oleg Kopyov who is MD, PhD, Executive Vice President and Chief Scientific Officer of LLC had attend the conference and conduct meetings to explore collaboration and funding opportunities for further development of Celavie’s human and veterinary clinical programs.
Meeting was about lead clinical program for the application of the company’s human undifferentiated allogeneic pluripotent stem cells in Parkinson’s disease (PD). Celavie also discussed their pre-clinical program in cerebellar ataxia and plans for taking their programs into further clinical development.

ABOUT THE COMPANY:

Celavie Biosciences is a privately-held company whose mission is to improve lives and restore hope in patients of central nervous system disease by advancing the regenerative stem cell therapies for the treatment of Parkinson’s disease and various other disorders of the central nervous system (CNS).
The company develops undifferentiated, unmodified allogeneic pluripotent stem cell-based therapies, holds a strong IP portfolio, including 18 issued patents, and has an experienced management team blending expertise in concept and cell technology, product scalability and entrepreneurship. Celavet, a subsidiary, applies the same proprietary technologies for the treatment and prevention of serious veterinary diseases.
More information is available at https://www.celavie.com/
To View source version log on to businesswire.com: https://www.businesswire.com/news/home/20191001005815/en/

Media Contact

Hannah Mongeon
LaVoieHealthScience
(802) 578-7124
hmongeon@lavoiehealthscience.com

ABOUT THE MEETING:

The Cell & Gene Meeting on the Mesa is the sector’s most famous annual conference held to bringing together the senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies by tackling the commercialization difficulty in facing the cell and gene therapy sector today. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 70+ dedicated presentations by the leading publicly traded and privately held companies in the space. This conference enables key partnerships through more than 2,200 one-on-one meetings while highlighting the significant clinical and commercial progress in the field by attracting over 1,150 attendees – over 20% of which are C-level executives.
For more information about the meeting, visit the website: https://www.meetingonthemesa.com/

    Tags: , ,